Pivotal Trial for an Automated AI-based System for Detection of Diabetic Retinopathy
Digital Diagnostics, Inc. · NCT07844317
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 22+ · All sexes
- Healthy volunteers
- Accepted
- Study type
- Observational
- Target enrollment
- 800
- US sites recruiting
- 1
- Study start
- August 24, 2026
- Record last updated
- September 28, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
Assessment of an autonomous AI system for diabetic retinopathy detection in adults with diabetes using retinal imaging.
Being studied: SaMD intended for the detection of diabetic retinopathy in adults with diabetes.; An AI/ML-based Software as a Medical Device (SaMD) for the automated detection of diabetic retinopathy in adults with diabetes.
Conditions: Diabetic Retinopathy (DR)
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- 22 years of age or older
- Diagnosis of DM
- Ability to understand and willing to sign a written ICF
Exclusion Criteria
Participants may be excluded if they have significant ocular conditions or prior ocular treatments that could interfere with retinal imaging or study assessments; are currently participating in another interventional ophthalmic clinical trial; have medical conditions that may affect study participation or data interpretation; are pregnant; or have contraindications to study-related imaging procedures.
Recruiting US locations
Rovia Site Network
Jacksonville, FL 32216
Site contact: Regional Director of Operations · 904-735-5466 · margot.wrenn@roviaclinical.com
Study contacts (from the official record)
- Audrey Singh Singh · 7633702127 · singh@digitaldiagnostics.com
Similar studies in Florida
All diabetes studies in Florida →- RecruitingHealthy volunteersPhase 1
Study of GS-4571 in Healthy Participants, Nondiabetic Obese Participants, and Nonobese Participants With Type 2 Diabetes Mellitus (T2DM)
Gilead Sciences
- Location
- Miami, FL + 2 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingHealthy volunteersPhase 1
A Trial Evaluating AMG 127 in Healthy Participants and Participants With Type 2 Diabetes Mellitus
Amgen
- Location
- Aventura, FL + 1 other US site
- Eligibility basics
- Ages 18–75
- RecruitingHealthy volunteersPhase 1
Phase I Study to Assess the Safety and Efficacy of OCU200 for Center-Involved Diabetic Macular Edema (DME)
Ocugen
- Location
- Deerfield Beach, FL + 4 other US sites
- Eligibility basics
- Ages 18+
- RecruitingHealthy volunteersPhase 1
Study to Evaluate if Exposure to Drug is Impacted in Participants With Renal Insufficiency
Sun Pharmaceutical Industries Limited
- Location
- Miami Lakes, FL
- Eligibility basics
- Ages 18–80